344897-95-6

中文名称 4-(5-((3-苄基-4-氧代-2-硫代噻唑烷-5-亚基)甲基)呋喃-2-基)苯甲酸

英文名称 Leukadherin 1

CAS 344897-95-6

分子式 C22H15NO4S2

分子量 421.49

MOL 文件 344897-95-6.mol

更新日期 2024/05/25 00:57:36

344897-95-6 结构式

基本信息物理化学性质安全数据 4-(5-((3-苄基-4-氧代-2-硫代噻唑烷-5-亚基)甲基)呋喃-2-基)苯甲酸价格(试剂级) 常见问题列表

基本信息

中文别名

4-(5-((3-苄基-4-氧代-2-硫代噻唑烷-5-亚基)甲基)呋喃-2-基)苯甲酸

英文别名

CS-2237
eukadherin-1
Leukadherin-1
Leukadherin 1
Leukadhedrin 1
LA1(Leukadherin-1)
LEUKADHERIN 1
LEUKADHERIN1
4-(5-((3-Benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid
4-[5-[[4-Oxo-3-(phenylmethyl)-2-thioxo-5-thiazolidinylidene]methyl]-2-furanyl]-benzoic acid
Benzoic acid, 4-[5-[[4-oxo-3-(phenylmethyl)-2-thioxo-5-thiazolidinylidene]methyl]-2-furanyl]-

物理化学性质

沸点634.7±65.0 °C(Predicted)

密度1.50±0.1 g/cm3(Predicted)

储存条件Sealed in dry,2-8°C

溶解度DMSO：可溶，3mg/mL，澄清（加热）

酸度系数(pKa)4.11±0.10(Predicted)

形态粉末

颜色黄色到橙色到棕色

安全数据

危险性符号(GHS)

GHS07,GHS08,GHS09

警示词危险

危险性描述H302-H410-H372

防范说明P260-P264-P273-P501

WGK Germany3

4-(5-((3-苄基-4-氧代-2-硫代噻唑烷-5-亚基)甲基)呋喃-2-基)苯甲酸价格(试剂级)

报价日期	产品编号	产品名称	CAS号	包装	价格
2024/04/30	HY-15701	4-(5-((3-苄基-4-氧代-2-硫代噻唑烷-5-亚基)甲基)呋喃-2-基)苯甲酸 Leukadherin-1	344897-95-6	5 mg	450元
2024/04/30	HY-15701	4-(5-((3-苄基-4-氧代-2-硫代噻唑烷-5-亚基)甲基)呋喃-2-基)苯甲酸 Leukadherin-1	344897-95-6	10mM * 1mLin DMSO	495元
2024/04/30	HY-15701	4-(5-((3-苄基-4-氧代-2-硫代噻唑烷-5-亚基)甲基)呋喃-2-基)苯甲酸 Leukadherin-1	344897-95-6	10mg	720元

常见问题列表

生物活性

Leukadherin-1 是特异性的白细胞表面整合素 CD11b/CD18 的激动剂。Leukadherin-1 可增加 CD11b/CD18 依赖性细胞对血纤蛋白原的粘附，EC50为 4 μM。Leukadherin-1 增强白细胞对配体 (如 ICAM-1) 和血管内皮的粘附，从而减少白细胞跨内皮迁移和流入损伤部位。Leukadherin-1 抑制先天性炎症信号转导。

体外研究

Leukadherin-1 is a specific agonist of the leukocyte surface integrin CD11b/CD18 (αMβ2; CR3; Mac-1). Leukadherin‐1 pretreatment reduces secretion of interferon (IFN)‐γ, tumour necrosis factor (TNF) and macrophage inflammatory protein (MIP)‐1β by monokine‐stimulated NK cells. Leukadherin‐1 pretreatment also reduces secretion of IL‐1β, IL‐6 and TNF by Toll‐like receptor (TLR)‐2 and TLR‐7/8‐stimulated monocytes.

体内研究

Leukadherin-1 (1 mg/kg; i.p.; twice daily for 14 days) is beneficial in preventing hyperoxia-induced neonatal lung injury, an experimental model of bronchopulmonary dysplasia (BPD).

Animal Model:	Newborn Sprague Dawley rat pups
Dosage:	1 mg/kg
Administration:	I.p.; twice daily for 14 days
Result:	Beneficial on preventing the lung inflammatory response, improved alveolarization and vascular development, and reduced pulmonary vascular remodeling and PH in a hyperoxia-induced experimental model of BPD.